Maximilian Diehn

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8153962/publications.pdf

Version: 2024-02-01

224 papers	36,737 citations	12303 69 h-index	3714 179 g-index
230 all docs	230 docs citations	230 times ranked	47518 citing authors

#	Article	IF	Citations
1	Robust enumeration of cell subsets from tissue expression profiles. Nature Methods, 2015, 12, 453-457.	9.0	8,460
2	The prognostic landscape of genes and infiltrating immune cells across human cancers. Nature Medicine, 2015, 21, 938-945.	15.2	2,505
3	Determining cell type abundance and expression from bulk tissues with digital cytometry. Nature Biotechnology, 2019, 37, 773-782.	9.4	2,396
4	Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature, 2009, 458, 780-783.	13.7	2,232
5	An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nature Medicine, 2014, 20, 548-554.	15.2	1,771
6	Downregulation of miRNA-200c Links Breast Cancer Stem Cells with Normal Stem Cells. Cell, 2009, 138, 592-603.	13.5	1,130
7	Integrated digital error suppression for improved detection of circulating tumor DNA. Nature Biotechnology, 2016, 34, 547-555.	9.4	837
8	Individuality and variation in gene expression patterns in human blood. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 1896-1901.	3.3	723
9	Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling. Cancer Discovery, 2017, 7, 1394-1403.	7.7	701
10	Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer. JAMA Oncology, 2020, 6, 650.	3.4	696
11	Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. Journal of Clinical Oncology, 2018, 36, 1631-1641.	0.8	668
12	Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients. Nature Communications, 2016, 7, 11815.	5.8	520
13	Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 5814-5819.	3.3	445
14	Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers. Nature Genetics, 2017, 49, 1693-1704.	9.4	423
15	Development and Validation of an Individualized Immune Prognostic Signature in Early-Stage Nonsquamous Nonâ€“Small Cell Lung Cancer. JAMA Oncology, 2017, 3, 1529.	3.4	412
16	Identification of noninvasive imaging surrogates for brain tumor gene-expression modules. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 5213-5218.	3.3	408
17	Integrating genomic features for non-invasive early lung cancer detection. Nature, 2020, 580, 245-251.	13.7	379
18	SOURCE: a unified genomic resource of functional annotations, ontologies, and gene expression data. Nucleic Acids Research, 2003, 31, 219-223.	6.5	376

#	Article	IF	Citations
19	Stereotyped and specific gene expression programs in human innate immune responses to bacteria. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 972-977.	3.3	371
20	Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA. Science Translational Medicine, 2016, 8, 364ra155.	5.8	348
21	Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma. Journal of Clinical Oncology, 2018, 36, 2845-2853.	0.8	313
22	Gene Expression Patterns in Ovarian Carcinomas. Molecular Biology of the Cell, 2003, 14, 4376-4386.	0.9	302
23	Genomic expression programs and the integration of the CD28 costimulatory signal in T cell activation. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 11796-11801.	3.3	300
24	Cell-type specific gene expression profiles of leukocytes in human peripheral blood. BMC Genomics, 2006, 7, 115.	1.2	275
25	Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer. Journal of Thoracic Oncology, 2021, 16, 1647-1662.	0.5	274
26	Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing. Blood, 2015, 125, 3679-3687.	0.6	270
27	Isolation and Molecular Characterization of Cancer Stem Cells in MMTV-Wnt-1 Murine Breast Tumors. Stem Cells, 2008, 26, 364-371.	1.4	262
28	Biochemical Interactions Integrating Itk with the T Cell Receptor-initiated Signaling Cascade. Journal of Biological Chemistry, 2000, 275, 2219-2230.	1.6	244
29	Large-scale identification of secreted and membrane-associated gene products using DNA microarrays. Nature Genetics, 2000, 25, 58-62.	9.4	241
30	Role of KEAP1/NRF2 and TP53 Mutations in Lung Squamous Cell Carcinoma Development and Radiation Resistance. Cancer Discovery, 2017, 7, 86-101.	7.7	239
31	Predicting HLA class II antigen presentation through integrated deep learning. Nature Biotechnology, 2019, 37, 1332-1343.	9.4	218
32	ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectalâ€“Anal Task Forces whitepaper. Nature Reviews Clinical Oncology, 2020, 17, 757-770.	12.5	218
33	FACTERA: a practical method for the discovery of genomic rearrangements at breakpoint resolution. Bioinformatics, 2014, 30, 3390-3393.	1.8	212
34	Cancer Stem Cells and Radiotherapy: New Insights Into Tumor Radioresistance. Journal of the National Cancer Institute, 2006, 98, 1755-1757.	3.0	207
35	Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint Inhibition. Cell, 2020, 183, 363-376.e13.	13.5	206
36	Transformation of follicular lymphoma to diffuse large-cell lymphoma: Alternative patterns with increased or decreased expression of c-myc and its regulated genes. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 8886-8891.	3.3	204

#	Article	IF	Citations
37	Circulating tumor DNA dynamics predict benefit from consolidation immunotherapy in locally advanced non-small-cell lung cancer. Nature Cancer, 2020, 1, 176-183.	5.7	201
38	Degradation of Proteins from the ER of S. cerevisiae Requires an Intact Unfolded Protein Response Pathway. Molecular Cell, 2000, 5, 729-735.	4.5	171
39	Transcriptional programs activated by exposure of human prostate cancer cells to androgen. Genome Biology, 2002, 3, research0032.1.	13.9	158
40	Early-Stage Nonâ€“Small Cell Lung Cancer: Quantitative Imaging Characteristics of¹⁸F Fluorodeoxyglucose PET/CT Allow Prediction of Distant Metastasis. Radiology, 2016, 281, 270-278.	3.6	152
41	Stereotactic ablative radiotherapy (SABR) for treatment of central and ultra-central lung tumors. Lung Cancer, 2015, 89, 50-56.	0.9	151
42	Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA. Nature Biotechnology, 2021, 39, 1537-1547.	9.4	151
43	Reprogramming the immunological microenvironment through radiation and targeting Axl. Nature Communications, 2016, 7, 13898.	5.8	150
44	Circulating Tumor DNA Analysis for Detection of Minimal Residual Disease After Chemoradiotherapy for Localized Esophageal Cancer. Gastroenterology, 2020, 158, 494-505.e6.	0.6	147
45	In Vivo Regulation of Human Skeletal Muscle Gene Expression by Thyroid Hormone. Genome Research, 2002, 12, 281-291.	2.4	143
46	Detection and Surveillance of Bladder Cancer Using Urine Tumor DNA. Cancer Discovery, 2019, 9, 500-509.	7.7	143
47	Dynamic Risk Profiling Using Serial Tumor Biomarkers for Personalized Outcome Prediction. Cell, 2019, 178, 699-713.e19.	13.5	138
48	Stereotactic Ablative Radiotherapy Should Be Combined With a Hypoxic Cell Radiosensitizer. International Journal of Radiation Oncology Biology Physics, 2010, 78, 323-327.	0.4	131
49	Therapeutic Implications of the Cancer Stem Cell Hypothesis. Seminars in Radiation Oncology, 2009, 19, 78-86.	1.0	130
50	Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. Archives of Pathology and Laboratory Medicine, 2018, 142, 1242-1253.	1.2	120
51	Atlas of clinically distinct cell states and ecosystems across human solid tumors. Cell, 2021, 184, 5482-5496.e28.	13.5	116
52	Detecting Liquid Remnants of Solid Tumors: Circulating Tumor DNA Minimal Residual Disease. Cancer Discovery, 2021, 11, 2968-2986.	7.7	116
53	Illuminating Radiogenomic Characteristics of Glioblastoma Multiforme through Integration of MR Imaging, Messenger RNA Expression, and DNA Copy Number Variation. Radiology, 2014, 270, 1-2.	3.6	109
54	A mathematical model of ctDNA shedding predicts tumor detection size. Science Advances, 2020, 6, .	4.7	105

#	Article	IF	Citations
55	The landscape of tumor cell states and ecosystems in diffuse large B cell lymphoma. Cancer Cell, 2021, 39, 1422-1437.e10.	7.7	102
56	Targeting Unique Metabolic Properties of Breast Tumor Initiating Cells. Stem Cells, 2014, 32, 1734-1745.	1.4	97
57	Predicting Radiotherapy Responses and Treatment Outcomes Through Analysis of Circulating Tumor DNA. Seminars in Radiation Oncology, 2015, 25, 305-312.	1.0	97
58	Neurotrophic factor GDNF promotes survival of salivary stem cells. Journal of Clinical Investigation, 2014, 124, 3364-3377.	3.9	96
59	KEAP1/NFE2L2 Mutations Predict Lung Cancer Radiation Resistance That Can Be Targeted by Glutaminase Inhibition. Cancer Discovery, 2020, 10, 1826-1841.	7.7	93
60	Molecular profiling of single circulating tumor cells from lung cancer patients. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E8379-E8386.	3.3	90
61	T Cell Receptor-Independent Basal Signaling via Erk and Abl Kinases Suppresses RAG Gene Expression. PLoS Biology, 2003, 1, e53.	2.6	88
62	ERBB2 -Mutated Metastatic Nonâ€“Small Cell Lung Cancer: Response and Resistance to Targeted Therapies. Journal of Thoracic Oncology, 2017, 12, 833-842.	0.5	86
63	Genome-Scale Identification of Membrane-Associated Human mRNAs. PLoS Genetics, 2006, 2, e11.	1.5	84
64	A phase II randomized trial of Observation versus stereotactic ablative RadiatIon for OLigometastatic prostate CancEr (ORIOLE). BMC Cancer, 2017, 17, 453.	1.1	83
65	Pulmonary Ventilation Imaging Based on 4-Dimensional Computed Tomography: Comparison With Pulmonary Function Tests andÂSPECT Ventilation Images. International Journal of Radiation Oncology Biology Physics, 2014, 90, 414-422.	0.4	81
66	Global analysis of shared TÂcell specificities in human non-small cell lung cancer enables HLA inference and antigen discovery. Immunity, 2021, 54, 586-602.e8.	6.6	80
67	Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy. Journal of Thoracic Oncology, 2021, 16, 1030-1041.	0.5	79
68	Stereotactic Ablative Radiotherapy for Reirradiation of Locally Recurrent Lung Tumors. Journal of Thoracic Oncology, 2012, 7, 1462-1465.	0.5	78
69	Potential clinical utility of ultrasensitive circulating tumor DNA detection with CAPP-Seq. Expert Review of Molecular Diagnostics, 2015, 15, 715-719.	1.5	75
70	GFPT2-Expressing Cancer-Associated Fibroblasts Mediate Metabolic Reprogramming in Human Lung Adenocarcinoma. Cancer Research, 2018, 78, 3445-3457.	0.4	75
71	Role of KEAP1/NFE2L2 Mutations in the Chemotherapeutic Response of Patients with Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2020, 26, 274-281.	3.2	75
72	Circulating Tumor DNA Analysis to Assess Risk of Progression after Long-term Response to PD-(L)1 Blockade in NSCLC. Clinical Cancer Research, 2020, 26, 2849-2858.	3.2	74

#	Article	IF	Citations
73	Control of inflammation by stromal Hedgehog pathway activation restrains colitis. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E7545-E7553.	3.3	73
74	Robust Intratumor Partitioning to Identify High-Risk Subregions in Lung Cancer: A Pilot Study. International Journal of Radiation Oncology Biology Physics, 2016, 95, 1504-1512.	0.4	71
75	Endothelial deletion of Ino80 disrupts coronary angiogenesis and causes congenital heart disease. Nature Communications, 2018, 9, 368.	5.8	71
76	A Population-Based Comparative Effectiveness Study of Radiation Therapy Techniques in Stage III Non-Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2014, 88, 872-884.	0.4	69
77	Normal Tissue Constraints for Abdominal and Thoracic Stereotactic Body Radiotherapy. Seminars in Radiation Oncology, 2017, 27, 197-208.	1.0	68
78	Tumor Volume-Adapted Dosing in Stereotactic Ablative Radiotherapy of Lung Tumors. International Journal of Radiation Oncology Biology Physics, 2012, 84, 231-237.	0.4	66
79	High-throughput sequencing for noninvasive disease detection in hematologic malignancies. Blood, 2017, 130, 440-452.	0.6	66
80	Single cell analysis reveals distinct immune landscapes in transplant and primary sarcomas that determine response or resistance to immunotherapy. Nature Communications, 2020, 11, 6410.	5.8	66
81	Galectin-1 Mediates Radiation-Related Lymphopenia and Attenuates NSCLC Radiation Response. Clinical Cancer Research, 2014, 20, 5558-5569.	3.2	64
82	Integrating Tumor and Stromal Gene Expression Signatures With Clinical Indices for Survival Stratification of Early-Stage Nonâ€“Small Cell Lung Cancer. Journal of the National Cancer Institute, 2015, 107, djv211.	3.0	64
83	Inferring gene expression from cell-free DNA fragmentation profiles. Nature Biotechnology, 2022, 40, 585-597.	9.4	63
84	Precision Hypofractionated Radiation Therapy in Poor Performing Patients With Non-Small Cell Lung Cancer: Phase 1 Dose Escalation Trial. International Journal of Radiation Oncology Biology Physics, 2015, 93, 72-81.	0.4	62
85	Colorectal Histology Is Associated With an Increased Risk of Local Failure in Lung Metastases Treated With Stereotactic Ablative Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2015, 92, 1044-1052.	0.4	61
86	Comparing functional genomic datasets: lessons from DNA microarray analyses of hostâ€“pathogen interactions. Current Opinion in Microbiology, 2001, 4, 95-101.	2.3	59
87	Deep segmentation networks predict survival of non-small cell lung cancer. Scientific Reports, 2019, 9, 17286.	1.6	59
88	Genetic Determinants of EGFR-Driven Lung Cancer Growth and Therapeutic Response In Vivo. Cancer Discovery, 2021, 11, 1736-1753.	7.7	59
89	Transcriptional response of human mast cells stimulated via the Fc(epsilon)RI and identification of mast cells as a source of IL-11. BMC Immunology, 2002, 3, 5.	0.9	56
90	Inhibition of Mouse Breast Tumor-Initiating Cells by Calcitriol and Dietary Vitamin D. Molecular Cancer Therapeutics, 2015, 14, 1951-1961.	1.9	56

#	Article	IF	Citations
91	Differential gene expression in anatomical compartments of the human eye. Genome Biology, 2005, 6, R74.	13.9	55
92	Erythropoietin promotes breast tumorigenesis through tumor-initiating cell self-renewal. Journal of Clinical Investigation, 2014, 124, 553-563.	3.9	53
93	4D CT lung ventilation images are affected by the 4D CT sorting method. Medical Physics, 2013, 40, 101907.	1.6	52
94	Type I collagen is overexpressed in medulloblastoma as a component of tumor microenvironment. Journal of Neuro-Oncology, 2008, 86, 133-141.	1.4	51
95	Lack of supporting data make the risks of a clinical trial of radiation therapy as a treatment for COVID-19 pneumonia unacceptable. Radiotherapy and Oncology, 2020, 147, 217-220.	0.3	49
96	Metabolic imaging metrics correlate with survival in early stage lung cancer treated with stereotactic ablative radiotherapy. Lung Cancer, 2012, 78, 219-224.	0.9	46
97	Combination Approach for Detecting Different Types of Alterations in Circulating Tumor DNA in Leiomyosarcoma. Clinical Cancer Research, 2018, 24, 2688-2699.	3.2	45
98	Case series of MET exon 14 skipping mutation-positive non-small-cell lung cancers with response to crizotinib and cabozantinib. Anti-Cancer Drugs, 2019, 30, 537-541.	0.7	41
99	Radiological tumour classification across imaging modality and histology. Nature Machine Intelligence, 2021, 3, 787-798.	8.3	41
100	High Retention and Safety of Percutaneously Implanted Endovascular Embolization Coils as Fiducial Markers for Image-Guided Stereotactic Ablative Radiotherapy of Pulmonary Tumors. International Journal of Radiation Oncology Biology Physics, 2011, 81, 85-90.	0.4	38
101	Impact of KEAP1/NFE2L2/CUL3 mutations on duration of response to EGFR tyrosine kinase inhibitors in EGFR mutated non-small cell lung cancer. Lung Cancer, 2019, 134, 42-45.	0.9	37
102	Short Diagnosis-to-Treatment Interval Is Associated With Higher Circulating Tumor DNA Levels in Diffuse Large B-Cell Lymphoma. Journal of Clinical Oncology, 2021, 39, 2605-2616.	0.8	37
103	A human lung tumor microenvironment interactome identifies clinically relevant cell-type cross-talk. Genome Biology, 2020, 21, 107.	3.8	33
104	Clinical Implications of KEAP1-NFE2L2 Mutations in NSCLC. Journal of Thoracic Oncology, 2021, 16, 395-403.	0.5	33
105	Clinical Implementation of Intrafraction Cone Beam Computed Tomography Imaging During Lung Tumor Stereotactic Ablative Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2013, 87, 917-923.	0.4	32
106	Early response evaluation using primary tumor and nodal imaging features to predict progression-free survival of locally advanced non-small cell lung cancer. Theranostics, 2020, 10, 11707-11718.	4.6	32
107	A 3-D Riesz-Covariance Texture Model for Prediction of Nodule Recurrence in Lung CT. IEEE Transactions on Medical Imaging, 2016, 35, 2620-2630.	5.4	31
108	Dosimetric Factors and Toxicity in Highly Conformal Thoracic Reirradiation. International Journal of Radiation Oncology Biology Physics, 2016, 94, 808-815.	0.4	31

#	Article	IF	Citations
109	Circulating tumor DNA testing in advanced non-small cell lung cancer. Lung Cancer, 2018, 119, 42-47.	0.9	31
110	Neuregulin Autocrine Signaling Promotes Self-Renewal of Breast Tumor-Initiating Cells by Triggering HER2/HER3 Activation. Cancer Research, 2014, 74, 341-352.	0.4	30
111	Deactivated CRISPR Associated Protein 9 for Minor-Allele Enrichment in Cell-Free DNA. Clinical Chemistry, 2018, 64, 307-316.	1.5	30
112	Mid-radiotherapy PET/CT for prognostication and detection of early progression in patients with stage III non-small cell lung cancer. Radiotherapy and Oncology, 2017, 125, 338-343.	0.3	29
113	Intrafraction Verification of Gated RapidArc by Using Beam-Level Kilovoltage X-Ray Images. International Journal of Radiation Oncology Biology Physics, 2012, 83, e709-e715.	0.4	27
114	Pre-treatment non-target lung FDG-PET uptake predicts symptomatic radiation pneumonitis following Stereotactic Ablative Radiotherapy (SABR). Radiotherapy and Oncology, 2016, 119, 454-460.	0.3	27
115	Identification and genetic manipulation of human and mouse oesophageal stem cells. Gut, 2016, 65, 1077-1086.	6.1	27
116	Functional significance of U2AF1 S34F mutations in lung adenocarcinomas. Nature Communications, 2019, 10, 5712.	5.8	27
117	Early prediction of clinical outcomes in resected stage II and III colorectal cancer (CRC) through deep sequencing of circulating tumor DNA (ctDNA).. Journal of Clinical Oncology, 2017, 35, 3591-3591.	0.8	27
118	Tumor Volume as a Potential Imaging-Based Risk-Stratification Factor in Trimodality Therapy for Locally Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2011, 6, 920-926.	0.5	26
119	Imaging Features Associated With Disease Progression After Stereotactic Ablative Radiotherapy for Stage I Nonâ€“Small-Cell Lung Cancer. Clinical Lung Cancer, 2014, 15, 294-301.e3.	1.1	25
120	Data normalization considerations for digital tumor dissection. Genome Biology, 2017, 18, 128.	3.8	25
121	38, 2424-2429.	1.6	24
122	Randomized Phase II Study of Preoperative Chemoradiotherapy Â± Panitumumab Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIa, N2+) Nonâ€“Small Cell Lung Cancer: NRG Oncology RTOG 0839. Journal of Thoracic Oncology, 2017, 12, 1413-1420.	0.5	22
123	18F-EF5 PET-based Imageable Hypoxia Predicts Local Recurrence in Tumors Treated With Highly Conformal Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2018, 102, 1183-1192.	0.4	22
124	To SABR or Not to SABR? Indications and Contraindications for Stereotactic Ablative Radiotherapy in the Treatment of Early-Stage, Oligometastatic, or Oligoprogressive Nonâ€“Small Cell Lung Cancer. Seminars in Radiation Oncology, 2015, 25, 78-86.	1.0	20
125	Capturing Genomic Evolution of Lung Cancers through Liquid Biopsy for Circulating Tumor DNA. Journal of Oncology, 2017, 2017, 1-5.	0.6	20
126	A Quantitative CT Imaging Signature Predicts Survival and Complements Established Prognosticators in Stage I Non-Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2018, 102, 1098-1106.	0.4	20

#	Article	IF	Citations
127	What the Diagnostic Radiologist Needs to Know about Radiation Oncology. Radiology, 2011, 261, 30-44.	3.6	19
128	Clinical impact of dose overestimation by effective path length calculation in stereotactic ablative radiation therapy of lung tumors. Practical Radiation Oncology, 2013, 3, 294-300.	1.1	19
129	Migration of implanted markers for imageâ€guided lung tumor stereotactic ablative radiotherapy. Journal of Applied Clinical Medical Physics, 2013, 14, 77-89.	0.8	19
130	Hypofractionated Intensity-Modulated Radiotherapy for Patients With Nonâ€“Small-Cell Lung Cancer. Clinical Lung Cancer, 2016, 17, 588-594.	1.1	19
131	The Myc Connection: ES Cells and Cancer. Cell, 2010, 143, 184-186.	13.5	18
132	Metastatic Cancer Stem Cells: An Opportunity for Improving Cancer Treatment?. Cell Stem Cell, 2010, 6, 502-503.	5.2	17
133	Analysis of Long-Term 4-Dimensional Computed Tomography Regional Ventilation After Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2015, 92, 683-690.	0.4	17
134	Prognostic value and molecular correlates of a CT image-based quantitative pleural contact index in early stage NSCLC. European Radiology, 2018, 28, 736-746.	2.3	17
135	Detection and Diagnostic Utilization of Cellular and Cell-Free Tumor DNA. Annual Review of Pathology: Mechanisms of Disease, 2021, 16, 199-222.	9.6	16
136	Vagal and recurrent laryngeal neuropathy following stereotactic ablative radiation therapy in the chest. Practical Radiation Oncology, 2014, 4, 272-278.	1.1	15
137	A Comprehensive Circulating Tumor DNA Assay for Detection of Translocation and Copy-Number Changes in Pediatric Sarcomas. Molecular Cancer Therapeutics, 2021, 20, 2016-2025.	1.9	15
138	Profiling of Circulating Tumor DNA for Noninvasive Disease Detection, Risk Stratification, and MRD Monitoring in Patients with CNS Lymphoma. Blood, 2021, 138, 6-6.	0.6	15
139	SABR-COMET: harbinger of a new cancer treatment paradigm. Lancet, The, 2019, 393, 2013-2014.	6.3	14
140	Genomic Profiling of Bronchoalveolar Lavage Fluid in Lung Cancer. Cancer Research, 2022, 82, 2838-2847.	0.4	14
141	Molecular and Immunologic Signatures are Related to Clinical Benefit from Treatment with Vocimagene Amiretrorepvec (Toca 511) and 5-Fluorocytosine (Toca FC) in Patients with Glioma. Clinical Cancer Research, 2020, 26, 6176-6186.	3.2	13
142	Circulating DNA for Molecular Response Prediction, Characterization of Resistance Mechanisms and Quantification of CAR T-Cells during Axicabtagene Ciloleucel Therapy. Blood, 2019, 134, 550-550.	0.6	13
143	A method for detecting and correcting feature misidentification on expression microarrays. BMC Genomics, 2004, 5, 64.	1.2	11
144	Long-Term Survival of a Patient With Nonâ€“Small-Cell Lung Cancer Harboring a V600E Mutation in the BRAF Oncogene. Clinical Lung Cancer, 2016, 17, e17-e21.	1.1	11

#	Article	IF	Citations
145	A population-based comparative effectiveness study of chemoradiation regimens and sequences in stage III non-small cell lung cancer. Lung Cancer, 2017, 108, 173-182.	0.9	11
146	The impact of audiovisual biofeedback on 4D functional and anatomic imaging: Results of a lung cancer pilot study. Radiotherapy and Oncology, 2016, 120, 267-272.	0.3	10
147	Noninvasive Genotyping and Assessment of Treatment Response in Diffuse Large B Cell Lymphoma. Blood, 2015, 126, 114-114.	0.6	10
148	Outcomes of Modestly Hypofractionated Radiation for Lung Tumors: Pre- and Mid-Treatment Positron Emission Tomography-Computed Tomography Metrics as Prognostic Factors. Clinical Lung Cancer, 2015, 16, 475-485.	1.1	9
149	Sinoatrial node toxicity after stereotactic ablative radiation therapy to lung tumors. Practical Radiation Oncology, 2017, 7, e525-e529.	1.1	9
150	Towards Non-Invasive Classification of DLBCL Genetic Subtypes By Ctdna Profiling. Blood, 2019, 134, 551-551.	0.6	9
151	Dynamic Noninvasive Genomic Monitoring for Outcome Prediction in Diffuse Large B-Cell Lymphoma. Blood, 2015, 126, 130-130.	0.6	9
152	Molecular Determinants of Radiation Response in Nonâ€“Small Cell Lung Cancer. Seminars in Radiation Oncology, 2015, 25, 67-77.	1.0	8
153	FLT-PET-CT for the Detection of Disease Recurrence After Stereotactic Ablative Radiotherapy or Hyperfractionation for Thoracic Malignancy: A Prospective Pilot Study. Frontiers in Oncology, 2019, 9, 467.	1.3	8
154	Development and Validation of Biopsy-Free Genotyping for Molecular Subtyping of Diffuse Large B-Cell Lymphoma. Blood, 2016, 128, 1089-1089.	0.6	8
155	Noninvasive Detection of Ibrutinib Resistance in Non-Hodgkin Lymphoma Using Cell-Free DNA. Blood, 2016, 128, 1752-1752.	0.6	8
156	Noninvasive Detection of BCL2, BCL6, and MYC Translocations in Diffuse Large B-Cell Lymphoma. Blood, 2016, 128, 2930-2930.	0.6	8
157	Feasibility and Potential Utility of Multicomponent Exhaled Breath Analysis for Predicting Development of Radiation Pneumonitis After Stereotactic Ablative Radiotherapy. Journal of Thoracic Oncology, 2014, 9, 957-964.	0.5	7
158	Noninvasive pulmonary nodule elastometry by CT and deformable image registration. Radiotherapy and Oncology, 2015, 115, 35-40.	0.3	7
159	Pulmonary function after lung tumor stereotactic ablative radiotherapy depends on regional ventilation within irradiated lung. Radiotherapy and Oncology, 2017, 123, 270-275.	0.3	6
160	Comprehensive Analysis of the Unfolded Protein Response in Breast Cancer Subtypes. JCO Precision Oncology, 2017, 2017, 1-9.	1.5	6
161	Local Recurrence Outcomes of Colorectal Cancer Oligometastases Treated With Stereotactic Ablative Radiotherapy. American Journal of Clinical Oncology: Cancer Clinical Trials, 2021, 44, 559-564.	0.6	6
162	Lung Volume Reduction After Stereotactic Ablative Radiation Therapy of Lung Tumors: Potential Application to Emphysema. International Journal of Radiation Oncology Biology Physics, 2014, 90, 216-223.	0.4	5

#	Article	IF	Citations
163	Time course and predictive factors for lung volume reduction following stereotactic ablative radiotherapy (SABR) of lung tumors. Radiation Oncology, 2016, 11, 40.	1.2	5
164	Predictors of Respiratory Decline Following Stereotactic Ablative Radiotherapy to Multiple Lung Tumors. Clinical Lung Cancer, 2019, 20, 461-468.e2.	1.1	5
165	Phased Variant Enrichment for Enhanced Minimal Residual Disease Detection from Cell-Free DNA. Blood, 2019, 134, 552-552.	0.6	5
166	Anatomic optimization of lung tumor stereotactic ablative radiation therapy. Practical Radiation Oncology, 2015, 5, e607-e613.	1.1	4
167	A Review of Immunotherapy for Stage III and Metastatic Non-Small Cell Lung Cancer and the Rationale for the ECOG-ACRIN EA5181 Study. Oncologist, 2021, 26, 523-532.	1.9	4
168	Leveraging phased variants for personalized minimal residual disease detection in localized non-small cell lung cancer.. Journal of Clinical Oncology, 2021, 39, 8518-8518.	0.8	4
169	Distinct Chromatin Accessibility Profiles of Lymphoma Subtypes Revealed By Targeted Cell Free DNA Profiling. Blood, 2018, 132, 672-672.	0.6	4
170	An Atlas of Clinically-Distinct Tumor Cellular Ecosystems in Diffuse Large B Cell Lymphoma. Blood, 2019, 134, 655-655.	0.6	4
171	Development of a Dynamic Model for Personalized Risk Assessment in Large B-Cell Lymphoma. Blood, 2017, 130, 826-826.	0.6	4
172	Predictive Radiation Oncology â€“ A New NCIâ€“DOE Scientific Space and Community. Radiation Research, 2022, 197, .	0.7	4
173	The effect of arm position on the dosimetry of thoracic stereotactic ablative radiation therapy using volumetric modulated arc therapy. Practical Radiation Oncology, 2014, 4, 192-197.	1.1	3
174	Comparison of Genomic Driver Oncogenes in Vietnamese Patients With Nonâ€“Small-Cell Lung Cancer in the United States and Vietnam. Journal of Global Oncology, 2018, 4, 1-9.	0.5	3
175	Stereotactic ablative radiotherapy for central and ultra-central lung tumors. Therapeutic Radiology and Oncology, 2019, 3, 18-18.	0.2	3
176	Response Letter: Radiation therapy for COVID-19 pneumopathy. Radiotherapy and Oncology, 2020, 149, 238-239.	0.3	3
177	Interim Circulating Tumor DNA As a Prognostic Biomarker in the Setting of Interim PET-Based Adaptive Therapy for DLBCL. Blood, 2019, 134, 1600-1600.	0.6	3
178	Profiling T-Cell Receptor Diversity and Dynamics during Lymphoma Immunotherapy Using Cell-Free DNA (cfDNA). Blood, 2020, 136, 49-50.	0.6	3
179	Prediction of therapeutic outcomes in DLBCL from circulating tumor DNA dynamics.. Journal of Clinical Oncology, 2016, 34, 7511-7511.	0.8	3
180	Early Assessment of Chemotherapy Response in Advanced Non-Small Cell Lung Cancer with Circulating Tumor DNA. Cancers, 2022, 14, 2479.	1.7	3

#	Article	IF	Citations
181	Practical workflow for rapid prototyping of radiation therapy positioning devices. Practical Radiation Oncology, 2017, 7, 442-445.	1.1	2
182	Line-Enhanced Deformable Registration of Pulmonary Computed Tomography Images Before and After Radiation Therapy With Radiation-Induced Fibrosis. Technology in Cancer Research and Treatment, 2018, 17, 153303461774941.	0.8	2
183	Invasive nodal evaluation prior to stereotactic ablative radiation for non-small cell lung cancer. Lung Cancer, 2018, 124, 76-85.	0.9	2
184	Increases in Serial Pretreatment 18F-FDG PET-CT Metrics Predict Survival in Early Stage Non-Small Cell Lung Cancer Treated With Stereotactic Ablative Radiation Therapy. Advances in Radiation Oncology, 2019, 4, 429-437.	0.6	2
185	Reply to J. Wang et al. Journal of Clinical Oncology, 2019, 37, 755-757.	0.8	2
186	A Feasibility Study of Single-inhalation, Single-energy Xenon-enhanced CT for High-resolution Imaging of Regional Lung Ventilation in Humans. Academic Radiology, 2019, 26, 38-49.	1.3	2
187	Stem Cells, Cell Differentiation, and Cancer. , 2020, , 97-107.e5.		2
188	Targeted Treatment of Multiple Primary Lung Cancers Harboring Distinct EGFR or RET Alterations: A Case Report. Clinical Lung Cancer, 2021, 22, e673-e677.	1.1	2
189	Overcoming Radioresistance of Lung Cancer Stem Cells. Stem Cells and Cancer Stem Cells, 2014, , 117-127.	0.1	2
190	Recurrent Crebbp Mutations in Follicular Lymphoma Appear Localized to the Committed B-Cell Lineage. Blood, 2020, 136, 30-31.	0.6	2
191	Inter- and intra-patient heterogeneity of resistance mechanisms to the mutant EGFR selective inhibitor rociletinib.. Journal of Clinical Oncology, 2016, 34, 9000-9000.	0.8	2
192	Noninvasive molecular subtyping and risk stratification of DLBCL.. Journal of Clinical Oncology, 2016, 34, 7554-7554.	0.8	2
193	Acute and Late Esophageal Toxicity After SABR to Thoracic Tumors Near or Abutting the Esophagus. International Journal of Radiation Oncology Biology Physics, 2022, 112, 1144-1153.	0.4	2
194	The Optimal Use of Radiotherapy in Small Cell Lung Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2013, 11, 107-114.	2.3	1
195	PS01.67: Case Series of MET Exon 14 Skipping Mutation-Positive Nonâ€“Small Cell Lung Cancers and Response to Crizotinib. Journal of Thoracic Oncology, 2016, 11, S312-S313.	0.5	1
196	MA17.07 Circulating Tumor DNA Detects Minimal Residual Disease and Predicts Outcome in Localized Lung Cancer. Journal of Thoracic Oncology, 2017, 12, S445.	0.5	1
197	Genomic feature selection by coverage design optimization. Journal of Applied Statistics, 2018, 45, 2658-2676.	0.6	1
198	Phased variants improve DLBCL minimal residual disease detection at the end of therapy.. Journal of Clinical Oncology, 2021, 39, 7565-7565.	0.8	1

#	Article	IF	Citations
199	Noninvasive identification of emergent mutations following cytotoxic therapy for lung cancer.. Journal of Clinical Oncology, 2021, 39, 8533-8533.	0.8	1
200	Mechanisms and Markers of Clinical Radioresistance. Cancer Drug Discovery and Development, 2020, , 63-96.	0.2	1
201	Stem Cells, Cell Differentiation, and Cancer. , 2014, , 98-107.e3.		1
202	Integrated digital error suppression for noninvasive detection of circulating tumor DNA in NSCLC.. Journal of Clinical Oncology, 2016, 34, e20500-e20500.	0.8	1
203	Absence of Evidence Implicating Hematopoietic Stem Cells As Common Progenitors for DLBCL Mutations. Blood, 2016, 128, 4107-4107.	0.6	1
204	Noninvasive Genotyping and Monitoring of Classical Hodgkin Lymphoma. Blood, 2018, 132, 2838-2838.	0.6	1
205	Tumor-Confirmed Follicular Lymphoma Mutations Are Detectable in Peripheral Blood Years Prior to Clinical Diagnosis. Blood, 2021, 138, 709-709.	0.6	1
206	Detection of Recurrence After Thoracic Stereotactic Ablative Radiotherapy Using FDG-PET-CT. Clinical Lung Cancer, 2022, 23, 282-289.	1.1	1
207	Mechanisms of Radioresistance in Cancer Stem Cells. , 2011, , 345-360.		0
208	In Reply to Song etÂal.. International Journal of Radiation Oncology Biology Physics, 2011, 81, 1194.	0.4	0
209	In Reply to Drs. Koch and Evans. International Journal of Radiation Oncology Biology Physics, 2011, 80, 1605.	0.4	0
210	Deep sequencing of circulating tumor DNA for personalized cancer detection and monitoring. Annals of Oncology, 2015, 26, vii3.	0.6	0
211	Noninvasive Cancer Classification Using Diverse Genomic Features in Circulating Tumor DNA. , 2016, , .		0
212	(OA02) Circulating Tumor DNA Quantitation for Early Response Assessment of Immune Checkpoint Inhibitors for Metastatic Non-Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2018, 101, e1-e2.	0.4	0
213	Noninvasive monitoring of cellular versus acellular tumor DNA from immunoglobulin genes for DLBCL.. Journal of Clinical Oncology, 2014, 32, 8504-8504.	0.8	0
214	Noninvasive and ultrasensitive quantitation of circulating tumor DNA by hybrid capture and deep sequencing.. Journal of Clinical Oncology, 2014, 32, 11016-11016.	0.8	0
215	Cancer Stem Cells and Tumor Radioresistance. , 2015, , 519-531.		0
216	Pre-treatment circulating tumor DNA as a biomarker for disease burden in diffuse large B cell lymphoma (DLBCL).. Journal of Clinical Oncology, 2015, 33, 8539-8539.	0.8	0

#	Article	IF	Citations
217	Distinct early response dynamics of circulating tumor DNA and circulating tumor cells during therapy of B-cell NHL.. Journal of Clinical Oncology, 2015, 33, 8570-8570.	0.8	0
218	Randomized phase II study of preoperative chemoradiotherapy (CRT)+/- Panitumumab (P) followed by consolidation chemotherapy (C) in potentially operable locally advanced (stage IIIa, N2+) non-small cell lung cancer (LANSCLC): Nrg oncology/RTOG 0839.. Journal of Clinical Oncology, 2016, 34, 8510-8510.	0.8	0
219	Sinoatrial node dysfunction after stereotactic ablative radiation therapy in the chest.. Journal of Clinical Oncology, 2017, 35, 132-132.	0.8	0
220	A phase II randomized trial of observation versus stereotactic ablative radiation for oligometastatic prostate cancer (ORIOLE).. Journal of Clinical Oncology, 2017, 35, TPS5094-TPS5094.	0.8	0
221	Lymphoma Virome Dynamics Revealed By Cell-Free DNA Sequencing. Blood, 2018, 132, 2861-2861.	0.6	0
222	Short Diagnosis-to-Treatment Interval Is Associated with Higher Levels of Circulating Tumor DNA in Aggressive B-Cell Non-Hodgkin Lymphoma. Blood, 2019, 134, 491-491.	0.6	0
223	Deep Sequencing of Viral Cell-Free DNA for Noninvasive Detection of Immunosuppression-Related Lymphoid Malignancies. Blood, 2019, 134, 885-885.	0.6	0
224	Noninvasive Cell-of-Origin Classification of Diffuse Large B-Cell Lymphoma Using Inferred Gene Expression from Cell-Free DNA Sequencing. Blood, 2021, 138, 37-37.	0.6	0